About Brett Wagner
Brett is the Search and Evaluation Manager at Douglas, where she leads the identification, assessment, and strategic evaluation of external opportunities that support the company’s growth and innovation objectives. In this role, Brett works closely with cross-functional teams across research, commercial, regulatory, and senior leadership to evaluate in-licensing, out-licensing, partnerships, CDMO opportunities, and emerging technologies, translating complex scientific and market data into clear, actionable insights.
Her work focuses on ensuring strategic alignment between potential opportunities and Douglas Pharmaceuticals’ capabilities, portfolio priorities, and long-term vision. Brett brings a rigorous, evidence-based approach to opportunity evaluation, balancing scientific validity with commercial, operational, and regulatory considerations to support high-quality decision-making.
Brett holds a PhD and has authored more than 40 peer-reviewed scientific publications, reflecting a strong foundation in research, data analysis, and critical evaluation. While her academic work has been internationally cited, her current focus is on applying this analytical expertise to real-world pharmaceutical strategy, helping Douglas Pharmaceuticals identify opportunities that deliver meaningful value for both patients and the organisation.
Her work focuses on ensuring strategic alignment between potential opportunities and Douglas Pharmaceuticals’ capabilities, portfolio priorities, and long-term vision. Brett brings a rigorous, evidence-based approach to opportunity assessment, balancing scientific validity with commercial, operational, and regulatory considerations to support high-quality decision-making.
Brett holds a PhD and has authored 40+ peer-reviewed scientific publications, reflecting a strong foundation in research, data analysis, and critical evaluation. While her academic work has been internationally cited, her current focus is on applying this analytical expertise to real-world pharmaceutical strategy, helping Douglas Pharmaceuticals identify opportunities that deliver meaningful value for both patients and the organisation.
Her work focuses on ensuring strategic alignment between potential opportunities and Douglas Pharmaceuticals’ capabilities, portfolio priorities, and long-term vision. Brett brings a rigorous, evidence-based approach to opportunity evaluation, balancing scientific validity with commercial, operational, and regulatory considerations to support high-quality decision-making.
Brett holds a PhD and has authored more than 40 peer-reviewed scientific publications, reflecting a strong foundation in research, data analysis, and critical evaluation. While her academic work has been internationally cited, her current focus is on applying this analytical expertise to real-world pharmaceutical strategy, helping Douglas Pharmaceuticals identify opportunities that deliver meaningful value for both patients and the organisation.
Her work focuses on ensuring strategic alignment between potential opportunities and Douglas Pharmaceuticals’ capabilities, portfolio priorities, and long-term vision. Brett brings a rigorous, evidence-based approach to opportunity assessment, balancing scientific validity with commercial, operational, and regulatory considerations to support high-quality decision-making.
Brett holds a PhD and has authored 40+ peer-reviewed scientific publications, reflecting a strong foundation in research, data analysis, and critical evaluation. While her academic work has been internationally cited, her current focus is on applying this analytical expertise to real-world pharmaceutical strategy, helping Douglas Pharmaceuticals identify opportunities that deliver meaningful value for both patients and the organisation.
Insights by Brett Wagner
Meet the Douglas CDMO team at AusBiotech 2024
Read articleYour guide to minimizing scope creep for pharma projects
Read articleTarget product profiles and Phase I clinical plans: laying the groundwork for success
Read articleMeet the Douglas CDMO team at AusBiotech 2025
Read articleWork with Brett Wagner’s team
Talk to Douglas CDMO about formulation, development and manufacturing for your molecule.
Get In Touch